Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
WMGI > SEC Filings for WMGI > Form 8-K on 18-Oct-2013All Recent SEC Filings

Show all filings for WRIGHT MEDICAL GROUP INC



Entry into a Material Definitive Agreement, Regulation FD Disclosure, Fi

Item 1.01 Entry into a Material Definitive Agreement.

On October 16, 2013, Wright Medical Group, Inc. (the "Company") entered into a Sale and Purchase Agreement (the "Purchase Agreement") with Upperside SA, a French société anonyme ("Upperside"), Naxicap Rendement 2018, a French société par actions simplifiée ("Naxicap"), and Banque Populaire Developpement, a French société anonyme (collectively, the "Sellers"). Under the terms of the Purchase Agreement, the Company will acquire 100% of the outstanding shares of Biotech International, a French société par actions simplifiée ("Biotech"). The transaction is expected to close in the fourth quarter of 2013, subject to the satisfaction of customary closing conditions.

The initial purchase price for the transaction is $75 million, consisting of $55 million payable in cash, subject to certain adjustments set forth in the Purchase Agreement, and the issuance of 742,115 unregistered shares of the Company's common stock having a value of $20 million. In addition, the Company will also pay up to $5 million upon the achievement of certain revenue milestones. The receipt of the Company's unregistered common stock by the Sellers is subject to customary "lock-up" restrictions whereby the Sellers may not transfer the stock for a period of one year from the date of closing.

The Purchase Agreement contains customary representations, warranties, covenants and indemnities. The closing of the transaction is subject to various conditions, including the transfer of Biotech's dental business, the repayment of certain existing loans, and the entry into certain transition services agreements between the Company and affiliates of Biotech.

The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement, which is filed as Exhibit 2.1 hereto and incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On October 16, 2013, the Company issued a press release. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) is being "furnished" and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
 Number    Description
  2.1      Sale and Purchase Agreement, dated as of October 16, 2013, by and among
           Upperside SA, Naxicap Rendement 2018, Banque Populaire Developpement,
           and Wright Medical Group, Inc.†
  99.1     Press Release of Wright Medical Group, Inc. dated October 16, 2013.

†Schedules and other similar attachments have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company hereby undertakes to furnish supplementally copies of any of the omitted schedules and attachments upon request by the United States Securities and Exchange Commission.

  Add WMGI to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for WMGI - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.